Standing up in public for a broader conception of value in healthcare.

17-24 of 60 News

viewpoint 5/04/17

On the Health Affairs Blog: Orphan Drugs, Pursuing Value, and Avoiding Unintended Effects of Regulations Joshua Liao and Mark Pauly explain why high prices are an unintended effect of government regulation, and suggest some potential solutions. READ MORE

viewpoint 5/03/17

On the Health Affairs Blog: Bateman-House, McBride-Folkers and Caplan Examine 'Right To Try" Bill Myths and Realities Alison Bateman-House, Kelly McBride-Folkers and Arthur Caplan discuss limitations in the Trickett Wendler Right to Try Act and suggest several measures for facilitating pre-approval access to drugs. READ MORE

viewpoint 5/01/17

On the Health Affairs Blog: FDA's Scott Gottlieb and the Goldilocks Theory Ian Spatz examines the challenges facing FDA commissioner Scott Gottleib and applies the "Goldilocks Theory" to the process of senators trying to determine if the FDA is too lenient or too tough in reviewing new prescription drugs. READ MORE

viewpoint 4/27/17

On the Health Affairs Blog: Lakdawalla, Sachs, and Bagley Focus on Medicaid’s Best-Price Rule and Trump Administration Opportunity to Advance Value-Based Pricing IVI’s Darius Lakdawalla, along with Rachel Sachs and Nicholas Bagley, examine how Medicaid’s best-price rule complicates the development of value-based pricing, and suggest a potential solution that could come out of new Trump administration CMS policies. READ MORE

viewpoint 4/24/17

On the Health Affairs Blog: Sood, Buckley and Strom Present a Win-Win Strategy for Improving Access to Hepatitis C Medicines Neeraj Sood, Gillian Buckley, and Brian Strom present a strategy to improve patient access to Hepatitis C medicines by having pharma patent holders license their patents to the federal government. READ MORE

viewpoint 4/14/17

In Health Affairs: Balancing the Use of Cost-Effectiveness Analysis in Healthcare Innovations IVI's Peter Neumann and James Baumgardner examine the reasons why the application of CEA technologies across different types of healthcare interventions are imbalanced, and suggest some possible ways in which the policies of government and private entities might change to address the issue. READ MORE

viewpoint 4/12/17

On the Health Affairs Blog: Assessing the Value of Treatments for Rare Diseases Presents Several Unique Challenges IVI's Darius Lakdawalla and Anupam Jena argue it's essential that value frameworks consider the potentially unique aspects of value that rare disease treatments provide. READ MORE

viewpoint 4/07/17

On the Health Affairs Blog: Rachel Sachs Summarizes Scott Gottlieb's FDA Commissioner Confirmation Hearing Calling it "remarkably unremarkable," Rachel Sachs summarizes Scott Gottlieb's recent FDA Commissioner confirmation hearing. READ MORE